MAP2K1 and adenocarcinoma: Kris et al. [9] in the multi-center study mentioned about two MEK1 positive adenocarcinoma patients, but their report limited only to the frequency (0.2 %) of the MEK1 mutation and any specific characteristic of these patients was not described.